Anti-CD30 Antibody [Ber-H8] (A279815)

Anti-CD30 Antibody [Ber-H8]

Mouse monoclonal [Ber-H8] antibody to CD30.

This antibody recognises CD30 also known as Ki-1 or TNFRSF8, a 120 kDa type I transmembrane glycoprotein receptor that belongs to the Tumor necrosis factor super family. CD30 is expressed by subpopulations of mitogen-stimulated T and B cell lymphoctyes and lymphoid neoplasms. CD30L, also known as TNSF8 or CD153 is the ligand of CD30. Once activated by its ligand, the receptor transduces the signal via the recruitment of TNFR-associated factor (TRAF) and TRAF associating proteins to form a signaling complex. This complex can subsequently activate NF?B and MAPK signaling pathways propagating anti-apoptotic/pro-survival responses. CD30 has been shown to be highly expressed in Hodgkin’s lymphoma and anaplastic large cell lymphoma. Some research has also indicated that CD30 is associated with a range of non-hematopoetic pathologies, including germ cell tumors and testicular embryonal carcinomas. This clone Ber-H8 has been used in flow cytometry experiments to measure CD30 surface expression levels on CD4+ cells upon treatment of cord blood with human heat shock protein 60.

Flow Cytometry, IHC-Fr, IHC-P

Human

Mouse

Monoclonal

Ber-H8

IgG1

Protein A affinity chromatography of tissue culture supernatant.

>95% (by SDS-PAGE).

Liquid

Supplied in Phosphate Buffered Saline with <0.1% Sodium Azide.

Store undiluted at 4°C. Do not freeze!

Mouse anti Human CD30, clone Ber-H8 recognizes CD30 also known as Ki-1 or TNFRSF8, a 120 kDa type I transmembrane glycoprotein receptor that belongs to the Tumor necrosis factor super family. CD30 is expressed by subpopulations of mitogen-stimulated T and B cell lymphoctyes and lymphoid neoplasms (Weyden et al. 2017). CD30L, also known as TNSF8 or CD153 is the ligand of CD30. Once activated by its ligand, the receptor transduces the signal via the recruitment of TNFR-associated factor (TRAF) and TRAF associating proteins to form a signaling complex. This complex can subsequently activate NF?B and MAPK signaling pathways propagating anti-apoptotic/pro-survival responses (Muta and Podack 2013). CD30 has been shown to be highly expressed in Hodgkin’s lymphoma and anaplastic large cell lymphoma. Some research has also indicated that CD30 is associated with a range of non-hematopoetic pathologies, including germ cell tumors and testicular embryonal carcinomas (Weyden et al. 2017). This clone Ber-H8 has been used in flow cytometry experiments to measure CD30 surface expression levels on CD4+ cells upon treatment of cord blood with human heat shock protein 60 (Aalbese et al. 2011).